Emerging Markets Report: Small Wonders
One World Pharma Inc. (OTCQB: OWPC) has announced a significant milestone by completing its first sale of cannabis plantlets in Colombia. The plantlets, which can be transplanted immediately, illustrate the company's secured licenses and the desirability of its superior genetic cannabis strains among growers. Current production capacity stands at 9,000 cuttings per cycle, with plans to double this to 18,000 by year-end, indicating strong potential for revenue growth. This development follows other positive news, such as high-level endorsements and regulatory approvals that further enhance market opportunities.
- First sale of cannabis plantlets in Colombia completed, showcasing operational capability.
- Cuttings can be produced within a 20-day cycle, with current capacity of 9,000 cuttings, doubling to 18,000 by year-end.
- Proven possession of necessary permissions and licenses to operate in Colombia.
- Strong demand for company's superior cannabis genetics from other growers.
- None.
Sale of Cannabis Cuttings Show Progress, Massive Potential for Isiah Thomas-led One World Pharma
An Emerging Markets Sponsored Commentary
ORLANDO, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- There are very few ‘Zoom Moments” in the market, when lightning strikes and massive markets and market caps arise instantaneously. The pandemic driven move to video conferencing company Zoom was clearly one of these moments.
But many times it’s the small wonders that can be proof of concept, tipping points even, simple marks of progress if you look close enough. And they can portend much greater things.
Last week, One World Pharma Inc. (OTCQB: OWPC) reported the first sale of cannabis plantlets in Colombia. Plantlets or “cuttings” are tiny germinated plants that can be immediately transplanted and grown in new areas. This cuts down on time and risk for the buyers and ensures OWP genetic quality of the mature plant.
For us, this is powerful news if you view it from the lens of what it proves. First, the plantlet sales in Colombia to other growers shows two things; that OWP has the permissions and licenses (in Colombia) to grow, and that the superior genetics that the Company has often referred to are highly desirable by other operators.
And the cuttings biz can be lucrative. According to OWP, “cuttings can be grown in a 20 day cycle with a current capacity of approximately 9,000 per cycle, with an expected scaling to a capacity of 18,000 cuttings per cycle by year end.”
That’s a lot of cuttings and of course, cuttings aren’t even the Company’s primary business.
Keep in mind that this cuttings announcement comes on the heels of these impressive news pieces:
NBA Star and Television Personality John Salley Joins One World Pharma's Board of Advisors
Colombian Ministry of Health Calls for International Export of Flower
Isiah Thomas pledges to put
One World Pharma Receives Colombian Approval for Five THC Strains
It’s a year’s worth of news for many companies, this potential for huge new markets to open, a CEO buying in, a celebrity joining the team, and Colombian approval of even MORE strains… all joining the small wonders of these tiny plants that simultaneously grow into elite cannabis ingredients and an ever expanding revenue stream.
For more information on One World Pharma please visit:
About Emerging Markets Report:
Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Must Read OTC Markets/SEC policy on stock promotion and investor protection
- https://www.otcmarkets.com/learn/policy-on-stock-promotion
- https://www.otcmarkets.com/learn/investor-protection
- https://www.sec.gov/news/press-release/2017-79
- https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid
Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave Suite 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
